Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion.
Impaired microvascular function during myocardial ischemia and reperfusion is associated with recruitment of polymorphonuclear neutrophils (PMN) and has been attributed to decreased bioavailability of nitric oxide (NO). Whereas myeloperoxidase (MPO), a highly abundant, PMN-derived heme protein facilitates oxidative NO consumption and impairs vascular function in animal models of acute inflammation, its capacity to function in this regard during human myocardial ischemia and reperfusion remains unknown. Plasma samples from 30 consecutive patients (61 +/- 14 years, 80% male) presenting with acute myocardial infarction were collected 9 +/- 4 h after vessel recanalization and compared to plasma from healthy control subjects (n = 12). Plasma levels of MPO were higher in patients than in control subjects (1.4 +/- 0.9 vs 0.3 +/- 0.2 ng/mg protein, respectively, p < 0.0001). The addition of hydrogen peroxide to patient plasma resulted in accelerated rates of NO consumption compared to control subjects (0.53 +/- 0.25 vs 0.068 +/- 0.039 nM/s/mg protein, respectively, p < 0.0001). Myocardial tissue from patients with the same pathology revealed intense recruitment of MPO-positive PMN localized along infarct-related vessels as well as diffuse endothelial distribution of non-PMN-associated MPO immunoreactivity. Endothelium-dependent microvascular function, as assessed by an acetylcholine-dependent increase in forearm blood flow in 75 patients with symptomatic coronary artery disease, inversely correlated with MPO plasma levels (r = -0.75, p < 0.005). Plasma from patients undergoing myocardial reperfusion contained increased levels of MPO, which catalytically consumed NO in the presence of H(2)O(2). Given the correlation between intravascular MPO levels and forearm vasomotor function in patients with coronary artery disease, MPO appears to be an important modulator of vasomotor function in inflammatory vascular disease and a potential therapeutic target for treatment.
Baldus
Stephan
S
Department of Cardiology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany. baldus@uke.uni-hamburg.de
Heitzer
Thomas
T
Eiserich
Jason P
JP
Lau
Denise
D
Mollnau
Hanke
H
Ortak
Michelle
M
Petri
Susan
S
Goldmann
Britta
B
Duchstein
Hans-Jürgen
HJ
Berger
Jürgen
J
Helmchen
Udo
U
Freeman
Bruce A
BA
Meinertz
Thomas
T
Münzel
Thomas
T
D000368:Aged; D000818:Animals; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006418:Heme / Q000737:chemistry; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009203:Myocardial Infarction / Q000097:blood; D017202:Myocardial Ischemia / Q000473:pathology*; D009206:Myocardium / Q000473:pathology; D009504:Neutrophils / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D009195:Peroxidase / Q000737:chemistry / Q000378:metabolism*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000737:chemistry; D011817:Rabbits; D012039:Regional Blood Flow; D015424:Reperfusion; D015427:Reperfusion Injury; D013997:Time Factors
D019408:Platelet Endothelial Cell Adhesion Molecule-1; D009569:Nitric Oxide; D006418:Heme; D006861:Hydrogen Peroxide; D009195:Peroxidase